Aurinia Pharmaceuticals Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $1.36 billion
- Book Value:
- Revenue TTM:
- $134.03 million
- Operating Margin TTM:
- Gross Profit TTM:
- $83.38 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Aurinia Pharmaceuticals Inc had its IPO on 1999-01-26 under the ticker symbol AUPH.
The company operates in the Healthcare sector and Biotechnology industry. Aurinia Pharmaceuticals Inc has a staff strength of 300 employees.
Shares of Aurinia Pharmaceuticals Inc opened at $9.48 at the start of the last trading session i.e. 2023-03-19.
The stocks traded within a range of $9.36 - $9.78, and closed at $9.51.
This is a -0.63% slip from the previous day's closing price.
A total volume of 2,529,000 shares were traded at the close of the day’s session.
In the last one week, shares of Aurinia Pharmaceuticals Inc have slipped by -0.21%.
Aurinia Pharmaceuticals Inc's Key Ratios
Aurinia Pharmaceuticals Inc has a market cap of $1.36 billion, indicating a price to book ratio of 1.5673 and a price to sales ratio of 4.9298.
In the last 12-months Aurinia Pharmaceuticals Inc’s revenue was $134.03 million with a gross profit of $83.38 million and an EBITDA of $-108764000. The EBITDA ratio measures Aurinia Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Aurinia Pharmaceuticals Inc’s operating margin was -83.17% while its return on assets stood at -13.74% with a return of equity of -24.46%.
In Q4, Aurinia Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 21.5%.
Aurinia Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.77 per share while it has a forward price to earnings multiple of 434.7826 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Aurinia Pharmaceuticals Inc’s profitability.
Aurinia Pharmaceuticals Inc stock is trading at a EV to sales ratio of 2.2884 and a EV to EBITDA ratio of -2.6157. Its price to sales ratio in the trailing 12-months stood at 4.9298.
Aurinia Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $470.86 million
- Total Liabilities
- $46.11 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Aurinia Pharmaceuticals Inc ended 2023 with $470.86 million in total assets and $0 in total liabilities. Its intangible assets were valued at $470.86 million while shareholder equity stood at $405.44 million.
Aurinia Pharmaceuticals Inc ended 2023 with $0 in deferred long-term liabilities, $46.11 million in other current liabilities, 1185309000.00 in common stock, $-864302000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $94.17 million and cash and short-term investments were $389.39 million. The company’s total short-term debt was $936,000 while long-term debt stood at $0.
Aurinia Pharmaceuticals Inc’s total current assets stands at $442.54 million while long-term investments were $0 and short-term investments were $295.22 million. Its net receivables were $13.48 million compared to accounts payable of $3.09 million and inventory worth $24.75 million.
In 2023, Aurinia Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Aurinia Pharmaceuticals Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Aurinia Pharmaceuticals Inc stock is currently trading at $9.51 per share. It touched a 52-week high of $13.415 and a 52-week low of $13.415. Analysts tracking the stock have a 12-month average target price of $13.
Its 50-day moving average was $8.64 and 200-day moving average was $7.97 The short ratio stood at 6.1 indicating a short percent outstanding of 0%.
Around 698.7% of the company’s stock are held by insiders while 3834.9% are held by institutions.
Frequently Asked Questions About Aurinia Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.